| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 06/30/2011 | US20110158957 Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases |
| 06/30/2011 | US20110158956 Treating cancer |
| 06/30/2011 | US20110158953 Tumor suppression through plexin c1 |
| 06/30/2011 | US20110158952 Compositions and methods for treating human papillomavirus-mediated disease |
| 06/30/2011 | US20110158948 Treatment Using Herpes Simplex Virus |
| 06/30/2011 | US20110158945 Myxoma virus mutants for cancer treatment |
| 06/30/2011 | US20110158944 Braf biomarkers |
| 06/30/2011 | US20110158943 Interferon alpha 2b modified by polyethylene glycol, the preparation and use thereof |
| 06/30/2011 | US20110158941 Crystalline recombinant interferon with altered spatial configuration, three-dimensional structure and uses thereof |
| 06/30/2011 | US20110158938 Il-15 binding site for il 15-ralpha and specific il-15 mutants having agonists / antagonists activity |
| 06/30/2011 | US20110158937 Synergistic stimulation of the immune system using immunostimulatory oligonucleotides and/or immunomer compounds in conjunction with cytokines and/or chemotherapeutic agents or radiation therapy |
| 06/30/2011 | US20110158936 Use of interleukin 17e for the treatment of cancer |
| 06/30/2011 | US20110158922 Skin Care Compositions and Method of Use Thereof |
| 06/30/2011 | US20110158915 Nanoshells with targeted enhancement of magnetic and optical imaging and photothermal therapeutic response |
| 06/30/2011 | US20110158906 Targeted block copolymer micelles |
| 06/30/2011 | US20110158905 Dock-and-Lock (DNL) Complexes for Therapeutic and Diagnostic Use |
| 06/30/2011 | US20110158903 One pot processes of preparing multifunctional liposome drug for imaging, delivery and targeting in cancer diagnosis and therapy |
| 06/30/2011 | US20110158902 Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers |
| 06/30/2011 | US20110155605 Apo-2 ligand |
| 06/30/2011 | DE102009060175A1 Pyrrolo[2,3-d] pyrazin-7-yl-pyrimidin-Verbindungen Pyrrolo [2,3-d] pyrazin-7-yl-pyrimidine compounds |
| 06/30/2011 | DE102009060174A1 Pyrrolopyridinyl-pyrimidin-2-yl-amin-derivate Pyrrolopyridinyl-pyrimidin-2-yl-amine derivatives |
| 06/30/2011 | CA2786950A1 Fused heteroaromatic pyrrolidinones as syk inhibitors |
| 06/30/2011 | CA2785503A1 Purified pyrroloquinolinyl-pyrrolidine-2,5-dione compositions and methods for preparing and using same |
| 06/30/2011 | CA2785492A1 Lipids, lipid compositions, and methods of using them |
| 06/30/2011 | CA2785410A1 Tyrosine bioconjugation through aqueous ene-like reactions |
| 06/30/2011 | CA2785409A1 Method for predicting therapeutic effects of chemotherapy on hepatocellular carcinoma patients |
| 06/30/2011 | CA2785389A1 Antitumor agent or postoperative adjuvant chemotherapeutic agent for hepatocellular carcinoma treatment |
| 06/30/2011 | CA2785340A1 Substituted isoquinolinones and quinazolinones |
| 06/30/2011 | CA2785329A1 Pyrrolo[2,3-d]pyrazin-7-ylpyrimidine compounds |
| 06/30/2011 | CA2785307A1 Pyrrolopyridinylpyrimidin-2-ylamine derivatives |
| 06/30/2011 | CA2785178A1 Anti-flt3 antibodies and methods of using the same |
| 06/30/2011 | CA2785021A1 Sustained-release formulation |
| 06/30/2011 | CA2784822A1 Phenol derivatives and pharmaceutical or cosmetic use thereof |
| 06/30/2011 | CA2784645A1 Methods and compositions related to annexin 1-binding compounds |
| 06/30/2011 | CA2784393A1 Compounds and methods for kinase modulation, and indications therefor |
| 06/30/2011 | CA2784385A1 Anti-bv8 antibodies and uses thereof |
| 06/30/2011 | CA2784345A1 Antibodies to non-functional oligomeric p2x7 receptors |
| 06/30/2011 | CA2784180A1 Seven-membered ring compound and pharmaceutical use therefor |
| 06/30/2011 | CA2783704A1 Carboxamide compounds and their use as calpain inhibitors |
| 06/30/2011 | CA2783616A1 (methylsulfonyl) ethyl benzene isoindoline derivatives and their therapeutical uses |
| 06/30/2011 | CA2783575A1 Aminopyrimidine kinase inhibitors |
| 06/30/2011 | CA2783475A1 Heterocyclic compounds as janus kinase inhibitors |
| 06/30/2011 | CA2783340A1 Inhibitors of akt activity |
| 06/30/2011 | CA2782571A1 Anti-her3 antibodies and uses thereof |
| 06/30/2011 | CA2780591A1 Anticancer combinations of artemisinin-based drugs and other chemotherapeutic agents |
| 06/30/2011 | CA2780177A1 Abt-263 capsule |
| 06/30/2011 | CA2687713A1 Treatment of cancer, arthritis, inflammation and other diseases by drawing on skin the big dose of vitamin e in oil and covering by film |
| 06/29/2011 | EP2339351A1 Non-peptide agonists and antagonists of adrenomedullin and gastrin releasing peptide |
| 06/29/2011 | EP2339035A1 Endogenous retroviruses up-regulated in prostate cancer |
| 06/29/2011 | EP2339020A1 Diagnostic methods based on Pregnancy-associated plasma protein-A (PAAP-A) |
| 06/29/2011 | EP2339003A2 APO-2 ligand substitutional variants |
| 06/29/2011 | EP2338994A1 Regulation of oncogenes by microRNAs |
| 06/29/2011 | EP2338993A1 Regulation of oncogenes by microRNAs |
| 06/29/2011 | EP2338917A1 Sulfated derivative of gastrodia elata polysaccharide, preparation method and use thereof |
| 06/29/2011 | EP2338915A2 Anti-VEGF antibodies |
| 06/29/2011 | EP2338914A1 Connective tissue growth factor antibodies |
| 06/29/2011 | EP2338899A1 Peptides for activation and inhibition of delta PKC |
| 06/29/2011 | EP2338892A1 Prostate specific membrane antigen inhibitors |
| 06/29/2011 | EP2338877A1 Combretastatin Derivatives and Uses Therefor |
| 06/29/2011 | EP2338525A2 Remote detection of substance delivery to cells |
| 06/29/2011 | EP2338524A1 Combined gene therapy for the treatment of macroscopic gliomas |
| 06/29/2011 | EP2338521A1 Lipopeptide- and lipoprotein-conjugates and its use |
| 06/29/2011 | EP2338518A1 Specific therapy using integrin ligands for treating cancer |
| 06/29/2011 | EP2338515A2 Antibodies that bind human interleukin-18 and methods of making and using |
| 06/29/2011 | EP2338509A2 Method of selecting patients suitable for WT1 vaccine |
| 06/29/2011 | EP2338507A1 Method of treating malignancies through induction of blood immune responses |
| 06/29/2011 | EP2338499A1 5' triphosphate oligonucleotide induces anti-viral response |
| 06/29/2011 | EP2338488A1 Drug combinations with substituted diaryl ureas for the treatment of cancer |
| 06/29/2011 | EP2338487A1 Combination therapy with PARP inhibitors |
| 06/29/2011 | EP2338486A1 3-(indolyl)- or 3-(azaindolyl)-4-arylmaleimide derivatives for use in the treatment of colon and gastric adenocarcinoma |
| 06/29/2011 | EP2338056A2 Chemical modulators of pro-apoptotic bax and bcl-2 polypeptides |
| 06/29/2011 | EP2338055A2 Monoclonal antibodies for cspg4 for the diagnosis and treatment of basal breast carcinoma |
| 06/29/2011 | EP2337868A1 Detection of granulosa-cell tumors |
| 06/29/2011 | EP2337795A2 Mhc multimers in cancer vaccines and immune monitoring |
| 06/29/2011 | EP2337782A1 Anti-tumor activity of aechl-i, a novel triterpenoid isolated from ailanthus excelsa in vitro and in vivo |
| 06/29/2011 | EP2337775A1 New 5-aminolevulinic acid prodrugs for use in photodynamic therapy and photodynamic diagnosis |
| 06/29/2011 | EP2337586A2 Method of production of polyanionic drug-carrier conjugates |
| 06/29/2011 | EP2337577A1 Use of pituitary adenylate cyclase-activating polypeptide (pacap) and pacap analogs as adjunctive treatments with anticancer agents |
| 06/29/2011 | EP2337561A1 Use of tocotrienol composition for the prevention of cancer |
| 06/29/2011 | EP2146986B1 Diphenyl-dihydro-imidazopyridinones |
| 06/29/2011 | EP2074122B1 Pyrido (2, 3-d) pyrimidin0ne compounds and their use as pi3 inhibitors |
| 06/29/2011 | EP2030978B1 Phosphine transition metal complex, method for producing the same and antitumor agent |
| 06/29/2011 | EP1981981B1 Anti-met monoclonal antibody, fragments and vectors thereof, for the treatment of tumors and corresponding products |
| 06/29/2011 | EP1928875B1 2-amino-7,8-dihydro-6H-pyrido(4,3-d)pyrimidin-5-ones, process for their preparation and pharmaceutical compositions containing the same |
| 06/29/2011 | EP1910336B1 Monohydrochloride monohydrate salt of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide |
| 06/29/2011 | EP1849774B1 CYCLOHEPTA(b)PYRIDINE-3-CARBONYLGUANIDINE DERIVATIVE AND PHARMACEUTICAL PRODUCT CONTAINING SAME |
| 06/29/2011 | EP1658097B1 Nucleotide and cellular vaccine composition |
| 06/29/2011 | EP1537147B9 Antibody anti hla-dr with an increased adcc and inducing cytokine production |
| 06/29/2011 | EP1326834B1 2-substituted heterocyclic compounds |
| 06/29/2011 | EP1322315B1 Formulations for reducing or eliminating toxicity of environmental hormones containing ursodeoxycholic acid |
| 06/29/2011 | EP1268306B1 Inverted aerosol dispenser |
| 06/29/2011 | EP1233958B1 Inhibitors of histone deacetylase |
| 06/29/2011 | EP1233943B1 Ionizable indolinone derivatives and their use as ptk ligands |
| 06/29/2011 | EP1183348B1 Compositions for the treatment and diagnosis of breast cancer and methods for their use |
| 06/29/2011 | EP1061915B1 Pharmaceutical formulations of taxanes |
| 06/29/2011 | EP0923932B1 Composition containing antitumor agent |
| 06/29/2011 | CN1960750B Therapeutic use of anti-CS1 antibodies |
| 06/29/2011 | CN1918298B Pharmaceutical composition and method of treatment of human malignancies with arginine deprivation |
| 06/29/2011 | CN1745843B Anticancer Chinese medicine compound preparation and its making method thereof |
| 06/29/2011 | CN1427889B Hybrid cells obtainable from antigen presenting cells |